SELECTIS HEALTH, INC. 8-K

What Happened
Selectis Health, Inc. filed an 8‑K on December 30, 2025, disclosing that effective December 31, 2025 it entered into a Third Amended and Restated Allonge and Modification Agreement (the “Third Allonge”) with holders of a majority of its 2018 11% Senior Secured Promissory Notes. As of the effective date, $1,775,000 in principal of the Notes were outstanding. The amendment extends the Notes’ maturity under specified conditions, raises the interest rate, extends related warrant expirations, and adds two directors.

Key Details

• Outstanding principal: $1,775,000 as of the Effective Date (12/31/2025).
• Maturity: extended to the earlier of (i) February 28, 2026, or (ii) the closing of a “Qualified Transaction” that yields sufficient net proceeds to retire all Notes; further extension possible in limited circumstances.
• Interest: accrues at 13% per annum until paid in full (up from 11%).
• Warrants: expiration extended to December 31, 2027; exercise price remains $2.25 per share.
• Corporate governance: Kent Lund and Lance Baller to join the Board effective January 1, 2026.
• Fees: Company will pay a $9,000 solicitation fee to GVC Capital LLC.
• Other: Noteholders’ rights continue to be governed by the existing Intercreditor Agreement.

Why It Matters
This amendment changes key debt terms that affect Selectis Health’s near‑term cash obligations and investor dilution risk. Higher interest (13%) increases the company’s cost of carrying the outstanding notes if they are not retired, while the maturity extension and the warrant extension delay cash repayment and potential equity issuance tied to the warrants. The board additions may reflect creditor influence or support for the amended terms. Retail investors should note the outstanding principal amount, tightened timelines for a qualifying transaction (or repayment by 2/28/2026), and the extended warrant life at $2.25 per share.